Henkel AG & Co KGaA (HELKF) reports robust financial performance with a 25% EPS increase and announces a significant share ...

In a report released today, Tom Sykes from Deutsche Bank maintained a Hold rating on Henkel AG & Co. KGaA (0IZC – Research Report), with a ...

In a report released today, Richard Felton from Goldman Sachs maintained a Buy rating on Fresenius Medical Care AG & Co. KGaA (0H9X – ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

The Federal Circuit reinstated a challenge of a Merck KGaA unit’s pigment patent by South Korea-based CQV Co. on Monday, ...